In conclusion, our single - center, retrospective analysis provides valuable insights into the real - world efficacy, survival, and safety of lorlatinib in patients with advanced NSCLC harboring ALK rearrangements. This evidence concerns the gene ALK and non-small cell lung carcinoma.